Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7798 · 5 trials · 5 indications
Summary of any adverse events and also by MedDRA SOC and Preferred term
Systolic and diastolic blood pressure will be summarized by descriptive statistics
Pulse rate will be summarized by descriptive statistics
The variables platelet count, red blood cell (RBC) count, haemoglobin, haematocrit will be summarized with descriptive statistics
The variables neutrophils, lymphocytes, monocytes, eosinophils, and basophils will be summarized with descriptive statistics
The variables mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and percentage of reticulocytes will be summarized with descriptive statistics
The variables creatinine and blood urea nitrogen (BUN) will be summarized with descriptive statistics
The variables potassium, sodium, and calcium will be summarized with descriptive statistics
The variables ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), and ALP (alkaline phosphatase), and albumin will be summarized with descriptive statistics
The variable hs-C-reactive protein will be summarized with descriptive statistics
The variable glucose will be summarized with descriptive statistics
12-lead ECGs will be obtained using an ECG machine, that automatically measures RR/HR, PR, QRS, QT and Corrected QT (QTc) intervals, and summarized with descriptive statistics
Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. It is based on: number of loose stools, abdominal pain, general well-being, extraintestinal complications, antidiarrheal agents used in the previous 7 days, abdominal mass felt on palpation, hematocrit and body weight
Standardized uptake value (SUV) is the radioactivity concentration in given region of interest normalized for injected radioactivity and body weight. Standardised uptake value ratio (SUVR) is the ratio of SUV in a given region of interest to a reference region without significant radioligand uptake
Kp is the partition coefficient that denotes radioactivity concentration ratio (area under the concentration-time curve \[AUC\] 0-60 min, intestines/AUC 0-60 min, blood). Kp denotes that denominator is the radioactivity measurement in blood (aorta), this is the reference region used in calculations. Percentage change in small bowel Kp from baseline (PET1 Visit) to PET2 visit is reported.
Kp is the partition coefficient that denotes radioactivity concentration ratio (area under the concentration-time curve \[AUC\] 0-60 min, intestines/AUC 0-60 min, blood). Kp denotes that denominator is the radioactivity measurement in blood (aorta), this is the reference region used in calculations. Percentage change in small bowel Kp from baseline (PET1 Visit) to PET3 visit is reported.
The safety and tolerability of AZD7798 following administration of single ascending doses will be assessed.
| Arm | Type | Description |
|---|---|---|
| AZD7798 | EXPERIMENTAL | AZD7798 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Panel 1 | EXPERIMENTAL | Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 1 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42. |
| Panel 2 | EXPERIMENTAL | Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 56. |
| Panel 3 | EXPERIMENTAL | Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 2 and Day 42. |
| Panel 4 | EXPERIMENTAL | Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 1 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42. |
| Panel 5 | EXPERIMENTAL | Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42. |
| Panel 6 | EXPERIMENTAL | Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by IV infusion of AZD7798 Dose Level 1 on Day 1 (Dose 1) and Day 15 (Dose 2). Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 28. |
| Part 1a - Cohort 1: AZD7798 dose 1 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Part 1a - Cohort 2: AZD7798 dose 2 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Part 1a - Cohort 3: AZD7798 dose 3 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Part 1a - Cohort 4: AZD7798 dose 4 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Part 1a - Cohort 5: AZD7798 dose 5 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Part 1a - Cohort 6: AZD7798 dose 6 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Part 1a - Cohort 7: AZD7798 dose 7 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Part 1b - Cohort 8: AZD7798 dose 8 | EXPERIMENTAL | A total of 6 subjects will receive repeat doses of AZD7798. |
| Part 1a - Spare Cohort 9: AZD7798 dose 9 | EXPERIMENTAL | A total of 6 subjects will receive a single ascending dose of AZD7798. |
| Part 2 - Cohort 10: AZD7798 + AZD7798 | EXPERIMENTAL | A total of 4 subjects will receive a single dose on Day 1 followed by a single dose on Day 15. |
| Part 2 - Cohort 11: Placebo + AZD7798 | EXPERIMENTAL | A total of 2 subjects will receive placebo on day 1 followed by AZD7798 on day 15. |
| Part 2 - Cohort 12: AZD7798 + Placebo | EXPERIMENTAL | A total of 2 subjects will receive AZD7798 on day 1 followed by placebo on day 15. |
| Placebo: Part 1a and Part 1b | EXPERIMENTAL | A total of 2 subjects per cohort will receive placebo. |
| Part 3a - Cohort 12: AZD7798 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Part 3b - Cohort 13: AZD7798 | EXPERIMENTAL | A total of 6 subjects will receive single ascending doses of AZD7798. |
| Placebo: Part 3a and Part 3b | EXPERIMENTAL | A total of 2 subjects per cohort will receive placebo. |
| Name | Type | Description |
|---|---|---|
| AZD7798 | DRUG | AZD7798 |
| Placebo | OTHER | Placebo |
| [11C]AZ14132516 | DRUG | A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination |
Inclusion Criteria: * 18 to 80 years of age. * Diagnosis of Crohn's disease established with clinical AND at least one of imaging, endoscopic, and/or histopathologic evidence. * Ileostomy (including Kock pouch) for at least 3 months. * Prior to screening endoscopy, clinical suspicion of active ilea...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
AZD7798 is an investigational small molecule being studied for the treatment of Crohn's disease, including moderate to severe forms of the condition. It is also being evaluated in healthy subjects as part of early clinical development. The drug is in clinical trials across multiple countries.
AZD7798 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials of AZD7798 in patients with Crohn's disease and in healthy volunteers.
AZD7798 is in Phase 1 and Phase 2 clinical development. Phase 1 trials have been completed, and Phase 2 trials are active but not recruiting participants. The drug is investigational and has not been approved by regulatory authorities.
AZD7798 has been studied in several clinical trials. NCT05452304 was a completed Phase 1 trial in healthy subjects and Crohn's disease patients. NCT06432764 was a completed PET imaging study. NCT06450197 is an active Phase 2a trial in moderate to severe Crohn's disease, and NCT06681324 is a Phase 2 trial in Crohn's disease patients with an ileostomy.
AZD7798 is a small molecule therapeutic being developed for Crohn's disease. Its specific molecular target has not been disclosed in public trial information. The drug is being evaluated for its safety, tolerability, and pharmacokinetics in early-stage studies.
Yes, AZD7798 has been tested in healthy volunteers. A completed Phase 1 trial, NCT05452304, included healthy subjects to assess the drug's safety, tolerability, and pharmacokinetics after single and repeat doses. This trial was conducted in the United Kingdom.